In this issue, Ferrante et al 3 led semistructured interviews with 32 lymphoma survivors and 13 lymphoma oncologists and advanced practice nurses to understand and characterize survivors' care ...

Lymphoma is the third most common cancer in US children, with Hodgkin and non-Hodgkin types affecting them differently. Common symptoms include swollen lymph nodes, fever, and fatigue, with diagnosis ...

Maryland Governor Larry Hogan and LRF Ambassador and Advocate Paul Majkowski share why Blood Cancer Awareness Month is an important tool in helping to raise awareness of lymphoma, bring the community ...

While being a caregiver can often be a rewarding experience, it can also be a very challenging one and may be harder on the caregiver than the patient. Thomas M. Habermann, MD of Mayo Clinic, ...

Improved biologic insight has led to the development of novel agents for non-Hodgkin lymphoma, which are now available in routine care. For patients with newly diagnosed diffuse large B-cell lymphoma, ...

Meghan Gutierrez leads the Lymphoma Research Foundation, the nation’s largest nonprofit devoted to funding lymphoma research and education. During the pandemic, the chief executive officer coordinated ...

The lymphatic system is the network of vessels, tissues, and organs that are part of the body’s immune system. Lymphoma develops in infection-fighting cells called lymphocytes that circulate through ...

Large B-cell lymphomas, with an estimated 150,000 new cases annually worldwide, represent almost 30% of all cases of non-Hodgkin’s lymphoma. Patients typically present with progressive lymphadenopathy ...

Epcoritamab can now be accessed as an option to treat relapsed or refractory follicular lymphoma in adults after 2 or more lines of systemic treatment, only if epcoritamab is stopped after 3 years of ...

In adults with advanced-stage Hodgkin’s lymphoma, the CD30-directed antibody–drug conjugate brentuximab vedotin combined with multiagent chemotherapy has been shown to have greater efficacy, but also ...